留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植治疗非酒精性脂肪性肝病的研究现状

杨洲 傅斌生

杨洲, 傅斌生. 肝移植治疗非酒精性脂肪性肝病的研究现状[J]. 器官移植, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017
引用本文: 杨洲, 傅斌生. 肝移植治疗非酒精性脂肪性肝病的研究现状[J]. 器官移植, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017
Yang Zhou, Fu Binsheng. Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017
Citation: Yang Zhou, Fu Binsheng. Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 419-423. doi: 10.3969/j.issn.1674-7445.2020.03.017

肝移植治疗非酒精性脂肪性肝病的研究现状

doi: 10.3969/j.issn.1674-7445.2020.03.017
基金项目: 

“十三五”国家科技部重大专项 2017ZX10203205

广东省自然科学基金科技项目 2017B030314027

广东省自然科学基金面上项目 2016A030313195

详细信息
    作者简介:

    杨洲,男,1993年生,硕士研究生,研究方向为肝移植,Email:1484439702@qq.com

    通讯作者:

    傅斌生,男,1979年生,博士,副主任医师,研究方向为肝移植、肝癌,E-mail:fubinsh@mail.sysu.edu.cn

  • 中图分类号: R617, R589.2

Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease

More Information
  • 摘要: 肝移植是治疗非酒精性脂肪性肝病(NAFLD)导致的相关终末期肝病的最有效手段。但是由于肥胖、代谢综合征等不良因素的影响,肝移植术后NAFLD的复发率很高。近年来,国内、外对NAFLD相关终末期肝病肝移植取得了一定的治疗进展。本文从NAFLD及肝移植治疗NAFLD等方面的研究进展进行综述。

     

  • [1] DRESCHER HK, WEISKIRCHEN S, WEISKIRCHEN R. Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)[J]. Cells, 2019, 8(8): E845. DOI: 10.3390/cells8080845.
    [2] WONG VW, CHAN WK, CHITTURI S, et al. Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33(1):70-85. DOI: 10.1111/jgh.13857.
    [3] BHATI C, IDOWU MO, SANYAL AJ, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis[J]. Transplantation, 2017, 101(8):1867-1874. DOI: 10.1097/TP.0000000000001709.
    [4] FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4):862-873. DOI: 10.1016/j.jhep.2017.06.003.
    [5] LI Z, XUE J, CHEN P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a Meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29(1):42-51. DOI: 10.1111/jgh.12428.
    [6] CARTER D, DIETERICH DT, CHANG C. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in liver transplantation[J]. Clin Liver Dis, 2018, 22(1):213-227. DOI: 10.1016/j.cld.2017.08.015.
    [7] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84. DOI: 10.1002/hep.28431.
    [8] LIU K, MCCAUGHAN GW. Epidemiology and etiologic associations of non-alcoholic fatty liver disease and associated HCC[J]. Adv Exp Med Biol, 2018, 1061:3-18. DOI: 10.1007/978-981-10-8684-7_2.
    [9] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases[J]. Hepatology, 2018, 67(1):328-357. DOI: 10.1002/hep.29367.
    [10] LEE SW, LEE TY, YANG SS, et al. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(2):176-180. doi: 10.1016/S1499-3872(16)60132-7
    [11] BEDOSSA P. Pathology of non-alcoholic fatty liver disease[J]. Liver Int, 2017, 37 (Suppl 1):85-89. DOI: 10.1111/liv.13301.
    [12] TANAKA N, KIMURA T, FUJIMORI N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research[J]. World J Gastroenterol, 2019, 25(2):163-177. DOI: 10.3748/wjg.v25.i2.163.
    [13] BZOWEJ NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation[J]. Curr Opin Organ Transplant, 2018, 23(2):169-174. DOI: 10.1097/MOT. 0000000000000502.
    [14] KERN B, FEURSTEIN B, FRITZ J, et al. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(2):205-210. DOI: 10.1097/MEG.0000000000001270.
    [15] LEWIN SM, MEHTA N, KELLEY RK, et al. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma[J]. Liver Transpl, 2017, 23(8):1015-1022. DOI: 10.1002/lt.24764.
    [16] YOUNOSSI ZM, LOOMBA R, RINELLA ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68(1):361-371. DOI: 10.1002/hep.29724.
    [17] CHITTURI S, WONG VW, CHAN WK, et al. The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups[J]. J Gastroenterol Hepatol, 2018, 33(1):86-98. DOI: 10.1111/jgh.13856.
    [18] ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4):829-846. DOI: 10.1016/j.jhep.2017.05.016.
    [19] GELLI C, TAROCCHI M, ABENAVOLI L, et al. Effect of a counseling-supported treatment with the mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2017, 23(17):3150-3162. DOI: 10.3748/wjg.v23.i17.3150.
    [20] DONG F, ZHANG Y, HUANG Y, et al. Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial[J]. Sci Rep, 2016, 6:36783. DOI: 10.1038/srep36783.
    [21] CONZEN KD, VACHHARAJANI N, COLLINS KM, et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis[J]. HPB (Oxford), 2015, 17(3):251-257. DOI: 10.1111/hpb.12340.
    [22] TSOCHATZIS E, COILLY A, NADALIN S, et al. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation[J]. Transplantation, 2019, 103(1): 45-56. DOI: 10.1097/TP.0000000000002433.
    [23] ESQUIVEL CM, GARCIA M, ARMANDO L, et al. Laparoscopic sleeve gastrectomy resolves NAFLD: another formal indication for bariatric surgery?[J]. Obes Surg, 2018, 28(12):4022-4033. DOI: 10.1007/s11695-018-3466-7.
    [24] PAIS R, BARRITT AS 4TH, CALMUS Y, et al. NAFLD and liver transplantation: current burden and expected challenges[J]. J Hepatol, 2016, 65(6):1245-1257. DOI: 10.1016/j.jhep.2016.07.033.
    [25] ALKHOURI N, HANOUNEH IA, ZEIN NN, et al. Liver transplantation for nonalcoholic steatohepatitis in young patients[J]. Transpl Int, 2016, 29(4):418-424. DOI: 10.1111/tri.12694.
    [26] SAAB S, LALEZARI D, PRUTHI P, et al. The impact of obesity on patient survival in liver transplant recipients: a Meta-analysis[J]. Liver Int, 2015, 35(1):164-170. DOI: 10.1111/liv.12431.
    [27] GERMANI G, LARYEA M, RUBBIA-BRANDT L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation[J]. Transplantation, 2019, 103(1):57-67. DOI: 10.1097/TP.0000000000002485.
    [28] PATEL YA, BERG CL, MOYLAN CA. Nonalcoholic fatty liver disease: key considerations before and after liver transplantation[J]. Dig Dis Sci, 2016, 61(5):1406-1416. DOI: 10.1007/s10620-016-4035-3.
  • 加载中
计量
  • 文章访问数:  149
  • HTML全文浏览量:  41
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-01-28
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-05-15

目录

    /

    返回文章
    返回